Gene · 6197
RPS6KA3: ribosomal protein S6 kinase A3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RPS6KA3: ribosomal protein S6 kinase A3. Genes, record 6197. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6197
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P51812 | Ribosomal protein S6 kinase alpha-3 | 740 | 15 | Ensembl, GeneID, HGNC |
Source UniProt
Patents36
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 10180 | P51812 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 10486 | P51812 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 10486 | P51812 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 10180 | P51812 | Espacenet |
| US 11884978 B2 | 2024-01-30 | 719 | P51812 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 74434 | P51812 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 177405 | P51812 | Espacenet |
| KR 1020210142125 A | 2021-11-24 | 3 | P51812 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 9806 | P51812 | Espacenet |
| US 10813931 B2 | 2020-10-27 | 34 | P51812 | Espacenet |
1 to 10 of 36
See all 36 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| TAS0612 | CHEMBL4650277 | p90RSK inhibitor | INHIBITOR |
Source ChEMBL
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,366
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RPS6KA3 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 20 | 2025 |
| R01CA046595 | Mitogenic and Oncogenic Regulation of ERK/RSK Signaling | 7 | 2025 |
| P30CA044579 | University of Virginia Cancer Center Support Grant | 6 | 2025 |
| P30CA043703 | Case Comprehensive Cancer Center Support Grant | 4 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 4 | 2025 |
| P30CA071789 | University of Hawaii Cancer Center CCSG | 4 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 3 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 3 | 2025 |
| P50CA136393 | Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancer | 3 | 2025 |
| R01CA196643 | Mechanisms of metabolic reprogramming by PIK3CA oncogenic mutations | 3 | 2025 |
1 to 10 of 1,366Source NIH's project files
See all 1,366 nih grantsPapers2,253
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrative phosphoproteomics reveals kinase-mediated regulation of OCIAD1 and its roles in mitochondrial quality control. | Front Bioinform | 2026 | 42564255 | PubTator, text mining | PubMed |
| A patent perspective of RSK inhibitors to treat cancer (2020-present). | Expert Opin Ther Pat | 2026 | 42508020 | PubTator, text mining | PubMed |
| The PDPK1-RSK2 axis as a potential convergent therapeutic vulnerability in B-cell lymphomas. | Expert Opin Ther Targets | 2026 | 42489440 | PubTator, text mining | PubMed |
| Discovery of a New Scaffold RSK2 Inhibitor With Virtual and Phenotypical Screening. | ChemMedChem | 2026 | 42363227 | PubTator, text mining | PubMed |
| Meta-cancer phosphoproteomic analysis unveils association of Tau phosphosites with DNA damage response. | Front Syst Biol | 2026 | 42254072 | PubTator, text mining | PubMed |
| MEK/ERK/RSK2 positive feedback loop modulates EMT to promote migration and invasion of triple-negative breast cancer through regulating GALNT5 mRNA stability. | Carcinogenesis | 2026 | 42236296 | PubTator, text mining | PubMed |
| [Coffin-Lowry syndrome: Case report in Mexico]. | Rev Med Inst Mex Seguro Soc | 2026 | 42096245 | PubTator, text mining | PubMed |
| Benzyl-Naphthoquinones as Selective Anticancer Agents for Oral Squamous Cell Carcinoma via Apoptosis Induction. | Biomedicines | 2026 | 42072298 | PubTator, text mining | PubMed |
| RPS6KA3/RSK2-mediated phosphorylation of DRAM2 promotes lysosomal targeting and autophagic flux in melanoma. | Autophagy | 2026 | 42059423 | PubTator, text mining | PubMed |
| Challenges in Diagnosis and Management of Coffin-Lowry Syndrome-Single-Center Experience. | Diagnostics (Basel) | 2026 | 41975704 | PubTator, text mining | PubMed |
1 to 10 of 2,253
See all 2,253 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6197
GET https://conductscience.org/api/genes/v1/6197/patents?page=2